Dana-Farber Master Class for Oncologists: Dallas

Location: Dallas, TX
Date: October 15-16, 2010

Meeting Overview

Venue:
The Westin City Center Dallas
Primary Audience:
Oncologists
Credits:
16.25 AMA PRA Category 1 CreditsTM

The latest science and guidelines brought to you by preeminent clinicians and researchers in oncology

Master Class for Oncologists is a CME program for oncologists brought to you by Dana-Farber Cancer Institute to share innovations in cancer care and research available nationally.

Learn about the latest science and guidelines from preeminent clinicians and researchers.
View Faculty Listing »

Educational Sessions

The educational program features 4 tracks:

  • Gastrointestinal Cancer
  • Breast Cancer
  • Hematologic Malignancies
  • Lung, Head, and Neck Cancers

Each track includes sessions and a panel led by expert faculty from Dana-Farber Cancer Institute and other leading clinical and academic centers of excellence. Attend as many sessions as fit your schedule and earn up to 16.25 AMA PRA Category 1 Credit(s)™.

Contribute to a Higher Standard of Patient Care

Dana-Farber Master Class for Oncologists offers the next generation of continuing education for oncologists, featuring intimately-sized meetings, direct access to expert faculty, and a focus on cutting-edge advances in oncology specialties. In addition to the completely updated curriculum, attendees can also participate in:

Supportive Care Session

Develop a comprehensive approach to managing the care of your cancer patients by attending this unique session: Caring for the Whole Patient: Supportive Care That Optimizes Treatment of the Physical, Psychological and Social Consequences of Cancer.

Genitourinary Session

Learn about recent advances, current expert opinions, best practices and emerging therapies in advanced and metastatic prostate cancer.

Educational Grants

To date, the following organizations have provided educational grants in support of this Pri-Med activity: Bristol-Myers Squibb Company, Celgene Corporation, Eisai, Inc., Genentech BioOncology , Genentech BioOncology and OSI Oncology , Lilly USA, LLC, and Novartis Oncology.

Session Topics

The educational program features 4 tracks focused on Breast, Upper Respiratory, Gastrointestinal and Hematologic cancers. Each track includes 5 sessions and a panel led by expert faculty from Dana-Farber Cancer Institute and other leading clinical and academic centers of excellence. Attend as many sessions as fit your schedule and earn AMA PRA Category 1 Credit(s).

View Schedule for:
Friday, October 15, 2010
6:30 AM-7:15 AM
Registration and Breakfast
7:15 AM-7:30 AM
Opening Remarks
7:30 AM-8:10 AM
Small Cell Lung Cancer: Best Practices and Recent Advances
Bruce E. Johnson, MD, Director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, Professor of Medicine, Harvard Medical School, Boston, MA
8:10 AM-8:50 AM
Non-Small Cell Lung Cancer: Molecular Insights and New Treatment Paradigms for Unique/Specific Cases (Part 1)
Pasi A. Janne, MD, PhD, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, Associate Professor of Medicine, Harvard Medical School, Boston, MA

Related CME

Featured CME Activities Format Credits Expires Status
EGFR Testing in Non-Small Lung Cancer: Practical Strategies That Incorporate Recent Clinical Advances Expert Perspective 1 AMA1
 08/04/2011
9:05 AM-9:30 AM
Non-Small Cell Lung Cancer: Molecular Insights and New Treatment Paradigms for Unique/Specific Cases (Part 2)
Pasi A. Janne, MD, PhD, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, Associate Professor of Medicine, Harvard Medical School, Boston, MA
9:30 AM-10:25 AM
Head and Neck Cancer Update: Combined Treatment Modalities and Comprehensive Management
Robert I Haddad, MD, Clinical Director, Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, MA, Associate Professor of Medicine, Harvard Medical School, Boston, MA

Related CME

Featured CME Activities Format Credits Expires Status
Head and Neck Cancer Update: Combined Treatment Modalities and Comprehensive Management Webcast 2 AMA1
 07/15/2011
Integrating Local and Systemic Therapies Into the Comprehensive Management of Head and Neck Cancer Expert Perspective 1 AMA1
 08/10/2011
10:25 AM-11:10 AM
Upper Respiratory Cancers Panel Discussion

Learning Objectives:

  1. Incorporate current clinical data and expert recommendations on the use of combined modalities to optimize treatment and improve outcomes for patients with head and neck cancers
  2. Develop a comprehensive approach to treating small cell lung cancer that includes current expert recommendations for initial effective therapy, appropriate use of prophylactic cranial irradiation, and continued management for survivors of the combined modality treatment
  3. Incorporate the recent molecular biomarkers into current best practices for the management of patients with both early and advanced stage non-small cell lung cancers
Pasi A. Janne, MD, PhD, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, Associate Professor of Medicine, Harvard Medical School, Boston, MA
Bruce E. Johnson, MD, Director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, Professor of Medicine, Harvard Medical School, Boston, MA
Robert I Haddad, MD, Clinical Director, Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, MA, Associate Professor of Medicine, Harvard Medical School, Boston, MA
11:25 AM-12:15 PM
Caring for the Whole Patient: Supportive Care That Optimizes Treatment of the Physical, Psychological and Social Consequences of Cancer

Learning Objectives:

  1. Develop a comprehensive approach to the management of debilitating cancer symptoms including pain, and nausea and vomiting
  2. Assess their current practices for optimal management of psychological and social sources of distress of cancer patients (including delirium) and reinforce if needed according to current expert recommendations
Janet L. Abrahm, MD , Adult Psychosocial Oncology Division, Dana-Farber Cancer Institute, Boston, MA, Associate Professor, Medicine and Anesthesia, Harvard Medical School, Boston, MA

Related CME

Featured CME Activities Format Credits Expires Status
Treating Pain in Cancer Patients: Recent Advances and Current Best Practices Expert Perspective 1 AMA1
 07/26/2011
Caring for the Whole Patient: Optimizing Treatment of the Physical Psychological and Social Consequences of Cancer Webcast 2 AMA1
 07/22/2011
12:15 PM-1:00 PM
Lunch
1:00 PM-1:50 PM
Genetic Syndromes and Gastrointestinal Cancers: A Practical Guide to Identifying and Managing Patients at Risk
Sapna Syngal, MD, MPH, Director, Familial Gastrointestinal Cancer Program, Dana-Farber/Brigham and Women???s Cancer Center, Boston, MA, Associate Professor of Medicine, Harvard Medical School, Boston, MA

Related CME

Featured CME Activities Format Credits Expires Status
Genetic Syndromes and Gastrointestinal Cancers: A Practical Guide to Identifying and Managing Patients at Risk Webcast 2 AMA1
 07/19/2011
1:50 PM-2:45 PM
Gastrointestinal Cancers and the Risk of Recurrence: Patient Lifestyle Changes that Make a Difference
Charles S. Fuchs, MD, MPH , Director, Harvard Cancer Center, Center for Gastrointestinal Oncology, Dana-Farber Cancer Institute, Boston, MA, Associate Professor of Medicine, Harvard Medical School, Boston, MA
3:00 PM-3:55 PM
Systemic Treatment for Colorectal Cancer in 2010
Robert J. Mayer, MD , Faculty Vice President for Academic Affairs, Dana-Farber Cancer Institute, Boston, MA, Stephen B. Kay Family Professor of Medicine, Harvard Medical School, Boston, MA
3:55 PM-4:45 PM
Multimodal Strategies for Esophageal, Gastric and Pancreatic Cancers: Update on Clinical Trial Results and Current Best Practices
Peter C. Enzinger, MD , Clinical Director, Center for Gastrointestinal Oncology, Dana-Farber Cancer Institute, Boston, MA, Assistant Professor of Medicine, Harvard Medical School, Boston, MA
5:00 PM-5:30 PM
Gastrointestinal Cancer Panel Discussion

Learning Objectives:

  1. Incorporate systemic therapies, surgery and radiation into multimodal management strategies for esophageal, gastric and pancreatic cancers, based on recent clinical trial results and current expert opinion
  2. Take patient histories that are designed to identify patients at high risk of a familial gastrointestinal cancer syndrome, use genetic testing effectively, and design management strategies that are appropriate for specific syndromes
  3. Understand and communicate to their patients specific lifestyle alterations and chemopreventative approaches that are likely to reduce the risk of recurrence in gastrointestinal cancer patients
  4. Choose the most appropriate systemic therapies for advanced and metastatic colorectal cancers, including adjuvant therapy when needed in earlier stage cancers, based on patient characteristics, current expert opinion and recent clinical trial results
Robert J. Mayer, MD , Faculty Vice President for Academic Affairs, Dana-Farber Cancer Institute, Boston, MA, Stephen B. Kay Family Professor of Medicine, Harvard Medical School, Boston, MA
Peter C. Enzinger, MD , Clinical Director, Center for Gastrointestinal Oncology, Dana-Farber Cancer Institute, Boston, MA, Assistant Professor of Medicine, Harvard Medical School, Boston, MA
Sapna Syngal, MD, MPH, Director, Familial Gastrointestinal Cancer Program, Dana-Farber/Brigham and Women???s Cancer Center, Boston, MA, Associate Professor of Medicine, Harvard Medical School, Boston, MA
Charles S. Fuchs, MD, MPH , Director, Harvard Cancer Center, Center for Gastrointestinal Oncology, Dana-Farber Cancer Institute, Boston, MA, Associate Professor of Medicine, Harvard Medical School, Boston, MA
5:30 PM-5:45 PM
Break and Light Refreshments
Saturday, October 16, 2010
6:30 AM-7:20 AM
Registration and Breakfast
7:20 AM-7:30 AM
Opening Remarks
7:30 AM-8:20 AM
Advanced and Metastatic Prostate Cancer: Patient Assessment and Current Best Practices and Emerging Therapies

Learning Objectives:

  1. Incorporate recent advances and current expert opinion into clinical management strategies for advanced and metastatic prostate cancers
  2. Choose appropriate systemic therapies for bladder cancer as part of a multimodal approach based on recent clinical trials and current expert opinion
  3. Assess the uses of current and emerging targeted therapies in renal cell carcinoma and make appropriate therapeutic choices based on current expert opinion
  4. Differentiate among good, intermediate and poor risk cases of testicular cancer and use these characteristics to design appropriate management strategies
Philip Kantoff, MD , Director, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, Professor of Medicine, Harvard Medical School, Boston, MA

Related CME

Featured CME Activities Format Credits Expires Status
Advanced and Metastatic Prostate Cancer: Patient Assessment, Current Best Practices and Emerging Therapies Webcast 2 AMA1
 07/12/2011
Recent Advances in Prostate Cancer: Emerging Therapies for Advanced Disease Expert Perspective 1 AMA1
 08/11/2011
8:20 AM-8:50 AM
Breast Cancer and Genetics: A Practical Guide to Identifying and Managing High Risk Patients
Judy E. Garber, MD, MPH, Director, Cancer Risk and Prevention Program, Dana-Farber Cancer Institute, Boston, MA, Associate Professor of Medicine, Harvard Medical School, Boston, MA

Related CME

Featured CME Activities Format Credits Expires Status
Guidelines for Cancer Genetic Testing and Management of Patients with BRCA Hereditary Breast Cancer Expert Perspective 1 AMA1
 07/06/2011
9:05 AM-9:55 AM
HER2+ and Triple Negative Breast Cancer
Eric P. Winer, MD, Chief, Division of Women's Cancers, Dana-Farber Cancer Institute, Boston, MA, Professor of Medicine, Harvard Medical School, Boston, MA
9:55 AM-10:45 AM
Hormone Receptor Positive Breast Cancer: Best Management Practices for Long Term Therapy
Harold J. Burstein, MD, PhD, Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, Associate Professor of Medicine, Harvard Medical School, Boston, MA

Related CME

Featured CME Activities Format Credits Expires Status
Hormone Receptor Positive Breast Cancer: Best Management Practices for Long Term Therapy Webcast 2 AMA1
 07/13/2011
11:00 AM-11:30 AM
Breast Cancer Survivorship Discussion: Optimizing Patient Outcomes by Incorporating Recent Expert Guidelines into Everyday Practice
Ann H. Partridge, MD, MPH, Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, Assistant Professor of Medicine, Harvard Medical School, Boston, MA
11:30 AM-12:00 PM
Breast Cancer Panel Discussion

Learning Objectives:

  1. Utilize current expert recommendations to formulate updated practices for identifying, testing and managing patients with genetic breast cancer syndromes
  2. Incorporate new and emerging therapies in their current management strategies for advanced breast cancer
  3. Design therapeutic strategies for women with hormone receptor positive breast cancer that optimize the potential for good outcomes while minimizing the potential side effects of long term therapy
  4. Utilize recent breast cancer survivorship guidelines to assess and update current surveillance practices and provide appropriate care for late or long term treatment effects
Judy E. Garber, MD, MPH, Director, Cancer Risk and Prevention Program, Dana-Farber Cancer Institute, Boston, MA, Associate Professor of Medicine, Harvard Medical School, Boston, MA
Eric P. Winer, MD, Chief, Division of Women's Cancers, Dana-Farber Cancer Institute, Boston, MA, Professor of Medicine, Harvard Medical School, Boston, MA
Harold J. Burstein, MD, PhD, Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, Associate Professor of Medicine, Harvard Medical School, Boston, MA
Ann H. Partridge, MD, MPH, Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, Assistant Professor of Medicine, Harvard Medical School, Boston, MA
12:00 PM-1:00 PM
Lunch
1:00 PM-1:45 PM
Treating Aggressive Lymphomas: Clinical Insights into Challenging Cases
Arnold S. Freedman, MD, Clinical Director, Lymphoma Program, Dana-Farber Cancer Institute, Boston, MA, Associate Professor of Medicine, Harvard Medical School, Boston, MA

Related CME

Featured CME Activities Format Credits Expires Status
Current and Emerging Therapeutic Approaches to Follicular Lymphoma Expert Perspective 1 AMA1
 07/23/2011
1:45 PM-2:40 PM
Update on Myeloid Malignancies: Incorporating New Strategies into Current Management Paradigms
Daniel J. DeAngelo, MD, PhD, Hematologic Malignancies Program, Dana-Farber Cancer Institute, Boston, MA, Associate Professor of Medicine, Harvard Medical School, Boston, MA
2:55 PM-3:30 PM
Best Practices in Myeloproliferative Neoplasms: Diagnosis, Treatment Goals and Effective Therapeutic Choices
Ayalew Tefferi, MD, Professor of Medicine and Hematology, Mayo Medical School, Rochester, MN

Related CME

Featured CME Activities Format Credits Expires Status
Mutational Analysis in Myeloproliferative Disorders: Impact on Prognosis and Therapeutic Choices Expert Perspective 1 AMA1
 08/04/2011
3:30 PM-4:05 PM
Multiple Myeloma: Continuing Evolution of the Clinical Landscape
Kenneth C. Anderson, MD, Director, Jerome Lipper Multiple Myeloma Center, Chief, Division of Hematologic Neoplasia, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA, Kraft Family Professor of Medicine, Harvard Medical School, Boston, MA

Related CME

Featured CME Activities Format Credits Expires Status
Multiple Myeloma: Incorporating Recent Clinical Trial Results into Current Management Practices Expert Perspective 1 AMA1
 08/18/2011
4:20 PM-5:00 PM
Chronic Lymphocytic Leukemia: Molecular Insights, Prognostic Factors, and Therapeutic Advances
John C. Byrd, MD , Director, Hematologic Malignancies Program, Ohio State University Medical Center, Columbus, OH
5:00 PM-5:30 PM
Hematologic Malignancies Panel Discussion

Learning Objectives:

  1. Assess recent clinical trials and incorporate new treatment strategies into existing management paradigms for the myeloid malignancies
  2. Describe and apply recent molecular advances to risk stratification and treatment selection for chronic lymphocytic leukemia
  3. Translate current expert guidance into best practices for diagnosis, treatment goals, and therapeutic choices in the myeloproliferative disorders
  4. Choose therapies for aggressive lymphomas based on current expert opinion, patient characteristics, and recent clinical data
  5. Modify clinical strategies on therapeutic choices for multiple myeloma to reflect up-to-date clinical data and current expert opinion
Richard M. Stone, MD, Director, Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA, Associate Professor of Medicine, Harvard Medical School, Boston, MA
Ayalew Tefferi, MD, Professor of Medicine and Hematology, Mayo Medical School, Rochester, MN
Arnold S. Freedman, MD, Clinical Director, Lymphoma Program, Dana-Farber Cancer Institute, Boston, MA, Associate Professor of Medicine, Harvard Medical School, Boston, MA
Kenneth C. Anderson, MD, Director, Jerome Lipper Multiple Myeloma Center, Chief, Division of Hematologic Neoplasia, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA, Kraft Family Professor of Medicine, Harvard Medical School, Boston, MA
John C. Byrd, MD , Director, Hematologic Malignancies Program, Ohio State University Medical Center, Columbus, OH

Related CME

Featured CME Activities Format Credits Expires Status
Emerging Therapeutic Choices for Acute Lymphocytic Leukemia Expert Perspective 1 AMA1
 08/10/2011

Accreditation

Credits Type Accreditation Statement Designation Statement
16.25 AMA PRA Category 1 Credits™ pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. pmiCME designates this educational activity for a maximum of 16.25 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.
Start:  End: 
Expand Expand Instructions Print PrintMap

Travel Arrangements

Meeting Location

The Westin City Center Dallas
650 N Pearl St
Dallas, TX 75201-2818
(214)979-9000
The Westin City Center Dallas web site

Hotel Accommodations

A limited number of rooms have been reserved at The Westin City Center Dallas. Please call (214)979-9000 by 09/23/2010 and identify yourself as a Master Class for Oncologists attendee to receive the discounted rate of $149.

Related CME

October 15-16, 2010

Featured Activities Format Credits ExpiresStatus
Multiple Myeloma: Incorporating Recent Clinical Trial Results into Current Management PracticesExpert Perspective1 AMA1
08/18/2011
Recent Advances in Prostate Cancer: Emerging Therapies for Advanced DiseaseExpert Perspective1 AMA1
08/11/2011
Integrating Local and Systemic Therapies Into the Comprehensive Management of Head and Neck CancerExpert Perspective1 AMA1
08/10/2011
Emerging Therapeutic Choices for Acute Lymphocytic LeukemiaExpert Perspective1 AMA1
08/10/2011
Mutational Analysis in Myeloproliferative Disorders: Impact on Prognosis and Therapeutic ChoicesExpert Perspective1 AMA1
08/04/2011
EGFR Testing in Non-Small Lung Cancer: Practical Strategies That Incorporate Recent Clinical AdvancesExpert Perspective1 AMA1
08/04/2011
Treating Pain in Cancer Patients: Recent Advances and Current Best PracticesExpert Perspective1 AMA1
07/26/2011
Current and Emerging Therapeutic Approaches to Follicular LymphomaExpert Perspective1 AMA1
07/23/2011
Caring for the Whole Patient: Optimizing Treatment of the Physical Psychological and Social Consequences of CancerWebcast2 AMA1
07/22/2011
Genetic Syndromes and Gastrointestinal Cancers: A Practical Guide to Identifying and Managing Patients at RiskWebcast2 AMA1
07/19/2011
Head and Neck Cancer Update: Combined Treatment Modalities and Comprehensive ManagementWebcast2 AMA1
07/15/2011
Hormone Receptor Positive Breast Cancer: Best Management Practices for Long Term TherapyWebcast2 AMA1
07/13/2011
Advanced and Metastatic Prostate Cancer: Patient Assessment, Current Best Practices and Emerging TherapiesWebcast2 AMA1
07/12/2011
Guidelines for Cancer Genetic Testing and Management of Patients with BRCA Hereditary Breast CancerExpert Perspective1 AMA1
07/06/2011

Additional Meetings

??
Other Recommended Meetings

Dana-Farber Master Class for Oncologists: Chicago - October 29, 2010 - October 30, 2010

Rosemont, IL

Meeting Overview | Register now | Add to my Outlook Calendar

Clinical Trials

Clinical Trial Resource Room

Back to top

The Clinical Trial Resource Room was developed by Dana-Farber to help oncologists navigate the complex landscape of clinical trials. Gain valuable insight about clinical trials and the requirements for trial participation directly from experts at Dana-Farber, identify appropriate trials for current patients and discuss recent and active trials with top industry researchers.

Track Directors

Track Directors information coming soon.

Additional Faculty